What Are Proton Pump Inhibitors?

Proton pump inhibitors (PPIs) are a group of medications that have been used to decrease the amount of acid in the stomach and intestines. Doctors prescribe PPIs to treat people with GERD, ulcers in the stomach or intestine, or other digestive disorders where the production of stomach acid needs to be controlled. Read more about what proton pump inhibitors are and what they do. Types of PPIs: Aciphex Dexilant Nexium Prevacid Prilosec Protonix Related Resources: GERD Erosive Esophagitis Zollinger-Ellison syndrome Peptic Ulcers What Are Proton Pump Inhibitors? originally appeared on About.com Heartburn / GERD on Monday, April 29th, 2013 at 22:00:51.Permalink | Comment | Email this
Source: About Heartburn / Acid Reflux - Category: Consumer Health News Source Type: news

Related Links:

(Mary Ann Liebert, Inc./Genetic Engineering News) Researchers report a growing awareness of gastroesophageal reflux problems among patients who undergo endoscopic, nonsurgical treatment for esophageal achalasia, frequently requiring future surgical intervention.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Conclusion The eradication rate of 10-day q.i.d. dual therapy was unacceptable, while that of the 14-day t.i.d. dual therapy was borderline acceptable for first-line therapy. The two dual therapies were well tolerated with few adverse effects.
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Gastroenterology Source Type: research
ConclusionAt 1 ‑year after esophagectomy, combination therapy with 30 mg lansoprazole and Esoxx® appears to be an effective antireflux strategy.
Source: European Surgery - Category: Surgery Source Type: research
This study is ai...
Source: BMC Pediatrics - Category: Pediatrics Authors: Tags: Research article Source Type: research
Conclusions: Our study results were not consistent with the hypothesis that PPI use increases MI risk among people without known heart disease.
Source: Epidemiology - Category: Epidemiology Tags: Cardiovascular Disease Source Type: research
Monday, April 6, 2020 (American Heart Association News) -- Doug Cobb popped a couple antacid pills to calm the heartburn he'd been experiencing on and off for weeks. The 60-year-old considered he might have a stomach problem, but waved it off,...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Abstract BACKGROUND: Health-related quality of life (HRQL) is an important outcome for chronic diseases such as diabetes mellitus that is associated with complications, comorbidities, and lifelong care. OBJECTIVES: The present study aims to explore the impact of comorbidities on the different dimensions of HRQL among type 2 diabetic patients attending primary care. METHODS: A total of 912 type 2 diabetic patients attending primary care centers in India were assessed using a predesigned and pretested questionnaire - Diabetes Comorbidity Evaluation Tool in Primary Care. The HRQL was measured by physical an...
Source: Primary Care - Category: Primary Care Authors: Tags: Prim Health Care Res Dev Source Type: research
Reflux hypersensitivity (RH), a functional esophageal disorder, is detected in 14% –20% of patients who present with typical esophageal symptoms. As many as 40% of patients with RH do not respond to treatment with pain modulators or proton pump inhibitors (PPIs); behavior disorders might contribute to lack of treatment efficacy. We aimed to assess the prevalence of behavioral di sorders and their effects on typical reflux symptoms in patients with RH.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
In this study, we have clarified the factors causing aggregate formation, focusing on the role of pharmaceutical additives and electrostatic interaction. Co-suspension of enteric-coated proton pump inhibitor (PPI) esomeprazole magnesium hydrate with levofloxacin resulted in aggregate formation, whereas the non-enteric-coated PPI vonoprazan fumarate did not. A comparison of pharmaceutical additive in the two PPIs highlighted polysorbate 80 and methacrylic acid copolymer LD as candidates causing aggregation. When these pharmaceutical additives were added to levofloxacin, only methacrylic acid copolymer LD induced aggregate f...
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
Authors: Puasripun S, Thinrungroj N, Pinyopornpanish K, Kijdamrongthum P, Leerapun A, Chitapanarux T, Thongsawat S, Praisontarangkul OA Abstract Background/Aims: The treatment of refractory functional dyspepsia (FD) is a challenge. Clidinium/chlordiazepoxide is a combination of antispasmodic and anxiolytic drugs that has been used as an adjunct treatment for FD in clinical practice with limited supporting evidence of efficacy. The aim of the study is to assess the efficacy and safety of clidinium/chlordiazepoxide as an adjunct treatment to a proton pump inhibitor (PPI) in refractory dyspepsia. Methods: We perfo...
Source: Journal of Neurogastroenterology and Motility - Category: Gastroenterology Tags: J Neurogastroenterol Motil Source Type: research
More News: Acid Reflux | Aciphex | Dexilant | Erosive Esophagitis | Esomeprazole | Gastroesophageal Reflux Disease | GERD | Heartburn | Lansoprazole | Nexium | Omeprazole | Pantoprazole | Peptic Ulcer | Prevacid | Prilosec | Proton Pump Inhibitors PPIs | Protonix | Zollinger-Ellison Syndrome